Marjolein P. A. Brekelmans
University of Amsterdam
Pulmonary embolismWarfarinEdoxabanThrombosisMedicine
What is this?
Publications 22
#1Lucia Mazzolai (UNIL: University of Lausanne)H-Index: 28
#2Victor Aboyans (French Institute of Health and Medical Research)H-Index: 52
Last. Marianne Brodmann (University of Graz)H-Index: 24
view all 17 authors...
33 CitationsSource
#1Alexander T. CohenH-Index: 22
Last. Carlos MartinezH-Index: 7
view all 3 authors...
#1Luuk J. J. Scheres (LUMC: Leiden University Medical Center)H-Index: 5
Last. A. DellucH-Index: 2
view all 13 authors...
OBJECTIVE: To investigate the characteristics and outcome of abnormal vaginal bleeding in women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE). DESIGN AND SETTING: Post hoc analysis of the Hokusai-VTE study, a multicentre, randomised, double-blind trial comparing edoxaban with warfarin for acute symptomatic VTE. POPULATION: Women below 50 years receiving edoxaban or warfarin for treatment of VTE. METHODS: We collected data on diagnostic measures, treatment, and clin...
5 CitationsSource
#1Thomas Vanassche (Katholieke Universiteit Leuven)H-Index: 16
#2Peter Verhamme (Katholieke Universiteit Leuven)H-Index: 32
Last. Harry R. BüllerH-Index: 92
view all 16 authors...
Abstract Background Many patients with venous thromboembolism (VTE) are elderly, have multiple comorbidities and take several concomitant medications. Physicians may prefer warfarin over direct oral anticoagulants (DOACs) in such patients because comparative data are lacking. This analysis was designed to determine the effects of advanced age, comorbidities, and polypharmacy on the efficacy and safety of edoxaban and warfarin in patients with VTE. Methods Using data from the Hokusai-VTE study, w...
2 CitationsSource
#2Harry R. BüllerH-Index: 92
Last. Jeffrey I. Weitz (McMaster University)H-Index: 90
view all 16 authors...
Pulmonary embolism (PE) studies used direct oral anticoagulants (DOACs) with or without initial heparin. We aimed to (1) evaluate if PE patients benefit from initial heparin; (2) describe patient characteristics in the DOAC studies; and (3) investigate whether the anatomical extent of PE correlates with N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, cause of PE, and recurrence rate. Our methods were (1) an indirect meta-analysis comparing the recurrence risk in DOAC-treated patient...
#2Rahat A. Abdoellakhan (UMCG: University Medical Center Groningen)H-Index: 3
Last. Michiel CoppensH-Index: 22
view all 11 authors...
Essentials Data on clinical outcome of vitamin K antagonist (VKA)-associated bleeds are scarce. Cohort study of patients with VKA bleeds treated with prothrombin complex concentrate (PCC). Effective haemostasis was achieved in 68% of patients with a VKA-associated bleeding. Thromboembolism rates were low and mortality rates high at 30 days after PCC administration. Background Vitamin K antagonists (VKA) are used for the treatment of thromboembolism. Patients with severe VKA-associated bleeding r...
2 CitationsSource
#1Noémie KraaijpoelH-Index: 6
#2Nick van EsH-Index: 17
Last. Harry R. BüllerH-Index: 92
view all 9 authors...
Cancer patients with venous thromboembolism (VTE) have a two- to six-fold increased risk of anticoagulant-related major bleeding events compared with VTE patients without cancer. It is unknown whether major bleeding events are more severe in cancer patients than in those without cancer. Individual patient data from four randomized phase III trials that compared factor Xa inhibitors and vitamin K antagonists for the treatment of VTE were used to compare the severity of major bleeding events in pa...
3 CitationsSource
#1Andria P. Medina (University of Oklahoma Health Sciences Center)H-Index: 3
#2Gary E. Raskob (University of Oklahoma Health Sciences Center)H-Index: 73
Last. Harry R. BüllerH-Index: 92
view all 16 authors...
Direct oral anticoagulants (DOACs) facilitate the outpatient treatment of venous thromboembolism (VTE). However, the pivotal trials of DOACs have not reported outcomes separately for patients managed either as outpatients or in the hospital. We performed a subgroup analysis of the Hokusai-VTE study comparing efficacy and safety of edoxaban with warfarin in 8,292 patients with acute VTE. Patients received initial therapy with open-label enoxaparin or unfractionated heparin for ≥5 days in the hosp...
2 CitationsSource
Factor Xa (fXa)-inhibitors are as effective and safer than vitamin-K–antagonists (VKA) in the treatment of venous thromboembolism (VTE). We previously classified the severity of clinical presentation and course of all major bleeding events from the EINSTEIN, AMPLIFY and HOKUSAI-VTE trials separately. The current aim was to combine these findings in order to increase precision, assess a class effect and analyse presentation and course for different types of bleeding, i. e. intracranial, gastro-in...
9 CitationsSource
#1Tom van der Hulle (LUMC: Leiden University Medical Center)H-Index: 7
#2Whitney CheungH-Index: 1
Last. A Del Sol MesaH-Index: 26
view all 35 authors...
Summary Background Validated diagnostic algorithms in patients with suspected pulmonary embolism are often not used correctly or only benefit subgroups of patients, leading to overuse of computed tomography pulmonary angiography (CTPA). The YEARS clinical decision rule that incorporates differential D-dimer cutoff values at presentation, has been developed to be fast, to be compatible with clinical practice, and to reduce the number of CTPA investigations in all age groups. We aimed to prospecti...
58 CitationsSource